Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDCD1 | Q15116 | 20/20 | 0.63 |
| ▸ | CD274 | Q9NZQ7 | 20/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29558234 | 1.00 | PDCD1 (0.63) | PDCD1CD274 | |
| SCHEMBL24446151 | 0.96 | PDCD1 (0.61) | PDCD1CD274 | |
| SCHEMBL24446142 | 0.93 | PDCD1 (0.58) | PDCD1CD274 | |
| SCHEMBL28783906 | 0.88 | PDCD1 (0.53) | PDCD1CD274 | |
| SCHEMBL28783898 | 0.86 | PDCD1 (0.86) | PDCD1CD274 | |
| SCHEMBL24659900 | 0.85 | PDCD1 (0.88) | PDCD1CD274 | |
| SCHEMBL29558570 | 0.85 | PDCD1 (0.88) | PDCD1CD274 | |
| SCHEMBL24446139 | 0.83 | PDCD1 (0.52) | PDCD1CD274 | |
| SCHEMBL22769812 | 0.82 | PDCD1 (0.67) | PDCD1CD274 | |
| SCHEMBL30522145 | 0.82 | PDCD1 (0.67) | PDCD1CD274 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220380342-A1 | BIPHENYL DERIVATIVES FOR BLOCKING PD-1/PD-L1 INTERACTION, PREPARATION METHOD THEREFOR AND USE THEREOF | ABBISKO THERAPEUTICS CO., LTD. (CN) | 2022-12-01 | — | — | US | disclosed |
| EP-4001274-A1 | BIPHENYL DERIVATIVES FOR BLOCKING PD-1/PD-L1 INTERACTION, PREPARATION METHOD THEREFOR AND USE THEREOF | Abbisko Therapeutics Co., Ltd. (CN) | 2022-05-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220380342-A1 | BIPHENYL DERIVATIVES FOR BLOCKING PD-1/PD-L1 INTERACTION, PREPARATION METHOD THEREFOR AND USE THEREOF | CD274, PDCD1, PDCD1LG2 | PDCD1 2/4885CD274 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.